Last updated: July 17, 2026

Application No. 18/722,189

COMBINATION OF AN A2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONIST WITH A NOREPINEPHRINE REUPTAKE INHIBITOR FOR THE TREATMENT OF SLEEP APNEA

Non-Final OA

Filed

Jun 20, 2024

Priority

Dec 22, 2021 — EU 21216872.8 +1 more

Examiner

KUCKLA, ANNA GRACE

Art Unit

Tech Center

Assignee

Bayer Aktiengesellschaft

OA Round

1 (Non-Final)

This examiner grants 50% of cases after interview

— +53.3% interview lift. A telephonic interview to clarify the technical implementation could significantly improve the outcome.

Based on 40 resolved cases, 2023–2026

Examiner Intelligence

KUCKLA, ANNA GRACE View full profile →

Grants 50% of resolved cases

Career Allowance Rate

20 granted / 40 resolved

-10.0% vs TC avg

Strong +53% interview lift

Without

With

+53.3%

Interview Lift

resolved cases with interview

Typical timeline

3y 3m

Avg Prosecution

42 currently pending

Career history

Total Applications

across all art units

Statute-Specific Performance

§103

43.6%

+3.6% vs TC avg

§102

23.4%

-16.6% vs TC avg

§112

6.9%

-33.1% vs TC avg

Black line = Tech Center average estimate • Based on career data from 40 resolved cases

Prosecution Timeline

Jun 20, 2024

Application Filed

Jun 02, 2026

Non-Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

18/040,667

Patent 12679844

IMIDAZOTRIAZINE AND PYRROLOPYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS

3y 5m to grant Granted Jul 14, 2026

17/755,780

Patent 12624004

OPIOID RECEPTOR AGONIST, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF

4y 0m to grant Granted May 12, 2026

17/626,904

Patent 12583875

PYRROMETHENE-BORON COMPLEX, COLOR CONVERSION COMPOSITION, COLOR CONVERSION FILM, LIGHT SOURCE UNIT, DISPLAY, AND ILLUMINATION DEVICE

4y 2m to grant Granted Mar 24, 2026

17/610,037

Patent 12577273

SMALL MOLECULE MODULATORS OF GUT BACTERIAL BILE ACID METABOLISM

4y 4m to grant Granted Mar 17, 2026

18/004,722

Patent 12577206

PYRAZOLONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS

3y 2m to grant Granted Mar 17, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2

Expected OA Rounds

50%

Grant Probability

99%

With Interview (+53.3%)

3y 3m (~1y 2m remaining)

Median Time to Grant

Low

PTA Risk

Based on 40 resolved cases by this examiner. Grant probability derived from career allowance rate.